 Hamilton, Bermuda, Jan. 10, 2023 GLOBE NEWSWIRE Company COO Dr. Pañeda will discuss SemaPhoreTM platforms functionality with mRNA, and: Peptide-based platform for extrahepatic delivery The extrahepatic success of, and prospects for, SemaPhore vs other liver-restricted delivery methods Altamira Therapeutics Ltd. NASDAQ:CYTO, a company dedicated to developing therapeutics that address important unmet medical needs, today... The post Altamira Therapeutics to Present at 2nd Annual mRNA-Based Th... 